Trazodone Monitoring Schedule: Labs & Exams Your Prescriber Should Order

Trazodone hydrochloride (brand names have included Desyrel and Oleptro) is a serotonin antagonist and reuptake inhibitor, or SARI, FDA-approved for major depressive disorder in adults. It is also widely prescribed off-label at lower doses for insomnia, a use the FDA has not evaluated or approved. This distinction matters for monitoring: a patient on 25-50 mg for sleep carries a different risk profile than one on 300 mg for depression, and no single monitoring schedule fits both without adjustment.

No FDA label or clinical guideline publishes a single codified "trazodone monitoring schedule." What follows is a synthesis built from the FDA prescribing information's warnings (hyponatremia, QT prolongation, hepatic caution, suicidality), general antidepressant-monitoring practice, and pharmacologic reasoning about how trazodone is metabolized and cleared. Where a specific interval or lab is standard clinical practice rather than a labeled requirement, that is noted. A prescriber may reasonably deviate from this schedule based on individual risk.

The core, quotable answer: trazodone therapy generally warrants baseline metabolic and blood count testing plus an ECG in patients with cardiac risk factors, a recheck 4 to 6 weeks after starting or changing dose, and then monitoring roughly every 6 to 12 months on a stable dose, with serum sodium checked more frequently in adults over 65 because of a recognized SIADH/hyponatremia risk described in the FDA label. This applies to oral trazodone at both insomnia and antidepressant dose ranges; it is a clinical framework, not a labeled requirement, and individual schedules should be set by the prescribing clinician based on age, comorbidities, and concurrent medications.

How trazodone works, and why that shapes what gets monitored

Trazodone blocks the serotonin 5-HT2A receptor and inhibits the serotonin transporter (SERT), while also antagonizing histamine H1 and alpha-1 adrenergic receptors. At the lower doses typically used for sleep (25-100 mg), the antihistamine and 5-HT2A effects dominate and produce sedation. At antidepressant doses (150-600 mg daily), serotonin reuptake inhibition becomes more clinically relevant, and with it, the risks that require closer lab follow-up.

Trazodone is metabolized in the liver, substantially through CYP3A4, to an active metabolite, meta-chlorophenylpiperazine (mCPP). Drugs that strongly inhibit CYP3A4 (certain antifungals, some antibiotics, some antivirals) can raise trazodone exposure; strong inducers can lower it. The exact magnitude of these interactions varies by drug and has not been quantified consistently enough here to state a precise fold-change; a pharmacist or the prescriber should be consulted before combining trazodone with a strong CYP3A4 inhibitor or inducer.

Each receptor target has a monitoring consequence: alpha-1 blockade causes orthostatic hypotension, which is why blood pressure checks matter; serotonergic activity is linked to SIADH and hyponatremia; and post-marketing reports have described dose-related QT prolongation, which is why cardiac risk factors and concomitant QT-prolonging drugs change the ECG plan.

Baseline labs and exams before starting trazodone

A baseline evaluation lets a clinician tell later abnormalities apart from pre-existing conditions.

• Comprehensive metabolic panel (CMP): liver enzymes, kidney function (BUN, creatinine, eGFR), electrolytes including sodium, and glucose. The FDA prescribing information warns about hyponatremia and about caution in hepatic impairment.
• CBC with differential: a baseline reference point. Hematologic effects such as leukopenia have been reported rarely with trazodone in case literature; a baseline count is standard practice for serotonergic antidepressants generally, not a trazodone-specific requirement.
• Thyroid-stimulating hormone (TSH): not specific to trazodone, but standard before starting treatment for depression or insomnia, since untreated thyroid disease can mimic or worsen both.
• Electrocardiogram (ECG): recommended for patients over roughly 50, those with known cardiac disease, and anyone already taking another QT-prolonging medication, given the FDA label's warning about QT prolongation and rare reports of torsades de pointes, particularly in overdose.
• Orthostatic blood pressure: lying and standing readings, since alpha-1 blockade makes orthostatic hypotension one of the more common side effects, with meaningful fall risk in older adults.

The 4-to-6-week follow-up

A recheck 4 to 6 weeks after starting or after any dose increase is reasonable clinical practice, timed to when side effects and early antidepressant response typically become apparent.

• Repeat the CMP, watching sodium in particular. A downward sodium trend, even one that stays within the normal range, is worth flagging rather than dismissing.
• Repeat the ECG if the baseline QTc was elevated or if the dose has increased above roughly 300 mg daily.
• Recheck orthostatic vitals at each visit during titration; a systolic drop of 20 mmHg or more on standing meets criteria for orthostatic hypotension and may prompt a slower titration or dose reduction.
• All antidepressants carry an FDA boxed warning about increased suicidal thinking in patients under 25. Structured suicide-risk assessment at baseline and at follow-up visits during the first weeks of treatment is standard practice for this age group, independent of trazodone specifically.

Ongoing monitoring on a stable dose

Once a patient has tolerated a stable dose through the 4-to-6-week check, many clinicians extend monitoring to every 6 to 12 months, adjusted for age and comorbidity.

Sodium in adults over 65

Antidepressant-associated hyponatremia through SIADH is described in the FDA label and in the broader antidepressant literature as more common in older adults, particularly those also on diuretics or with low baseline sodium. Published incidence estimates for trazodone specifically vary across studies and populations; a precise percentage is not stated here because it would overstate the certainty of any single figure. A reasonable practice for patients 65 and older is to check sodium at around 2 weeks, 4 weeks, and then quarterly through the first year, tightening the interval if any risk factor is present.

Signs that warrant an unscheduled lab draw

New confusion, lethargy, nausea, or seizure can signal hyponatremia. Unexplained bruising or recurrent infection can signal a hematologic effect. Jaundice or right-upper-quadrant pain can signal a hepatic problem. Syncope, palpitations, or new dizziness can signal a cardiac issue. Any of these warrants prompt evaluation rather than waiting for the next scheduled panel, and some (seizure, syncope, chest pain) warrant urgent or emergency care.

Cardiac monitoring: what actually changes the plan

The FDA label warns about QT prolongation and rare torsades de pointes, especially in overdose and with concomitant QT-prolonging drugs. There is no trazodone-specific QTc threshold endorsed by a regulatory body. The threshold used in practice, a QTc above 500 ms or an increase of 60 ms or more from baseline as grounds to reduce or stop a QT-prolonging drug, comes from FDA guidance issued for citalopram; it is commonly extrapolated to other QT-prolonging psychiatric drugs, including trazodone, but that extrapolation itself has not been validated in a trazodone-specific trial and should be treated as a reasonable clinical convention rather than an established, drug-specific rule.

Monitoring intensity decision framework

Use this to translate a patient's dose and risk factors into an actual monitoring tier. It is a clinical judgment tool for discussion with a prescriber, not a substitute for individualized medical advice.

Step 1: What dose range?

• Low dose for insomnia (roughly 25-100 mg): baseline CMP/CBC/TSH reasonable; ECG only if cardiac risk factors present.
• Antidepressant dose (150-600 mg): baseline ECG is more strongly indicated regardless of age, given greater serotonergic and QT-relevant exposure.

Step 2: Any of these risk flags present?

• Age 65 or older
• Baseline QTc at or above 450 ms
• Concurrent QT-prolonging drug (methadone, certain antipsychotics, ondansetron, certain fluoroquinolones)
• Concurrent diuretic use or known low baseline sodium
• Hepatic or severe renal impairment
• Age under 25 (suicidality monitoring track, not cardiac)

Step 3: Match to a tier.

• No flags, low dose: baseline labs, follow-up at 4-6 weeks, then annually.
• One flag: add the specific surveillance for that flag (sodium checks if 65+; ECG at 4-6 weeks if QT risk; transaminases every 4-6 weeks for 3 months if hepatic impairment) on top of the standard schedule.
• Two or more flags, or QTc 470-500 ms: consider whether trazodone is the right choice at all before starting, or tighten every interval above by roughly half (e.g., sodium every 2 weeks instead of monthly) and involve the patient's other prescribers about interacting drugs.
• QTc above 500 ms: this is a stop-and-reassess point; do not initiate, and if already on trazodone, discuss tapering with the prescriber promptly.

This framework narrows a broad "check labs periodically" instruction into a decision a reader can actually act on with their prescriber, but it does not replace an individualized cardiac or psychiatric risk assessment.

Hepatic and renal function

Trazodone undergoes substantial hepatic metabolism, and the FDA label advises caution in hepatic impairment without specifying an exact dose-adjustment table. In practice, some clinicians start at a reduced dose in significant liver disease and check liver enzymes every 4 to 6 weeks for the first few months. Trazodone and its metabolites are cleared substantially through the kidney; the exact proportion excreted unchanged versus as metabolites varies by source, and a precise percentage is not asserted here pending verification against the current label. Mild to moderate renal impairment typically does not require dose changes, but more severe impairment warrants closer attention to accumulation and side effects, which the standard CMP already captures.

Special populations

Adults over 65. Beyond sodium and orthostatic monitoring, falls are a real concern given alpha-1 blockade and age-related pharmacokinetic changes. A baseline and follow-up ECG, orthostatic vitals at every visit, and a simple fall-risk check (such as a Timed Up and Go test) are reasonable additions.

Patients under 25. The FDA boxed warning on antidepressant-associated suicidality calls for close monitoring, commonly operationalized as weekly visits for the first 4 weeks, then less frequent visits through week 12, with structured mood and suicidality checks at each contact. Lab monitoring otherwise follows the standard adult schedule.

Pregnancy and lactation. Controlled data in pregnant women are limited. If trazodone is used during pregnancy, additional fetal monitoring and observation of the newborn for withdrawal or serotonergic effects after delivery are reasonable, at the obstetric provider's discretion. Reference sources describe generally low relative infant dose estimates for trazodone in breastfeeding, though individual case data are limited; a lactation consultant or the prescriber should be involved in this decision rather than relying on a general summary.

Drug interactions that change the monitoring plan

• CYP3A4 inhibitors or inducers: can meaningfully raise or lower trazodone exposure. Any new interacting medication is a reason to recheck the CMP and consider an ECG within one to two weeks, and to discuss dose adjustment with the prescriber.
• Other serotonergic drugs (SSRIs, SNRIs, tramadol, triptans, MAOIs): raise the risk of serotonin syndrome. There is no single lab test that diagnoses serotonin syndrome; a creatine kinase level can help rule out rhabdomyolysis in a suspected case, but the diagnosis rests on clinical findings such as clonus, agitation, hyperthermia, and hyperreflexia. Sudden onset of these symptoms is an urgent-care or emergency situation, not something to monitor at home.
• Other QT-prolonging drugs (methadone, certain antipsychotics, ondansetron, certain fluoroquinolones): warrant a baseline ECG before combining, then a repeat at around one and four weeks.

Consolidated timeline

What is established, what is plausible, and what is not established

Established by the FDA label and general pharmacology: trazodone carries warnings for hyponatremia/SIADH, QT prolongation with rare torsades de pointes reports, hepatic caution, and the class-wide boxed warning on suicidality in patients under 25. It is metabolized through CYP3A4 to an active metabolite, and interacting drugs can change its exposure.

Plausible but not rigorously quantified for trazodone specifically: the exact incidence of hyponatremia at various ages, the precise magnitude of CYP3A4-interaction effects, and the exact QTc thresholds that should trigger action for trazodone as opposed to other serotonergic drugs. These numbers exist in the broader antidepressant literature but a trazodone-specific, well-replicated figure was not confirmed for this draft and should be verified against current primary literature before being stated as fact.

Not established: there is no FDA-mandated or guideline-codified "trazodone monitoring schedule." Every interval in this article reflects reasonable extrapolation from the label and general psychiatric and cardiology practice, not a single authoritative source, and a prescriber may reasonably use a different schedule based on the individual patient.

Common questions

What blood tests are typically ordered before starting trazodone? A comprehensive metabolic panel, a CBC with differential, and TSH are common baseline tests, chosen because they capture liver enzymes, kidney function, sodium, and thyroid status, all relevant to trazodone's warnings and to ruling out confounding conditions.

How often are labs repeated while on trazodone? A common pattern is a recheck 4 to 6 weeks after starting or changing dose, then every 6 to 12 months on a stable dose, with more frequent sodium checks in patients 65 and older.

Does trazodone always require an ECG? Not for every patient. It is more strongly indicated in patients over roughly 50, those with cardiac history, those on higher antidepressant doses, and those taking other QT-prolonging medications. A young, healthy patient on a low sleep dose may not need one.

Can trazodone cause low sodium? Yes, through SIADH, a mechanism described in the FDA label. Risk appears to be higher in older adults, those on diuretics, and those with low baseline sodium. Confusion, nausea, headache, or in severe cases seizure are reasons to seek prompt evaluation.

Is there a specific test for priapism risk? No. Priapism is a rare, serious, and unpredictable adverse effect described in the FDA label. There is no lab test that predicts it. A sustained, painful erection lasting more than four hours is a urologic emergency and needs immediate care, not monitoring.

References

• U.S. Food and Drug Administration. Trazodone hydrochloride prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018207s032lbl.pdf
• National Library of Medicine. Trazodone. Drugs and Lactation Database (LactMed). https://www.ncbi.nlm.nih.gov/books/NBK501922/

Additional literature on trazodone pharmacology, hyponatremia incidence, and cardiac risk was reviewed in preparing earlier drafts of this page but could not be independently verified against the primary source for this revision. Specific numeric claims from that literature have been removed or narrowed pending verification by a qualified medical reviewer with access to the original papers.